Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
BUSINESS
Gene Techno CEO Eyes Lucentis Biosimilar Launch in November 2021, Expects Share of “At Least 30%”
Gene Techno Science plans to file what could be Japan’s first Lucentis (ranibizumab) biosimilar as early as September, aiming for its approval a year later and its listing and launch in November 2021, President and CEO Masaharu Tani said in…
To read the full story
Related Article
- Lucentis, Rituxan Biosimilars Win Label Expansions
September 28, 2023
- Kidswell Bio Revs Up Biosimilar Push, G-Lasta, Eylea Follow-Ons in Development
February 22, 2023
- Lucentis Biosimilar Now Approved for Diabetic Macular Edema
January 16, 2023
- 1st Lucentis Biosimilar Launched in Japan, Senju Eyes 6.9 Billion Yen in 5th Year
December 10, 2021
- Lucentis Biosimilar Filed in Japan; Senju/Gene Techno Eye 2021 Approval
September 23, 2020
- As Beovu Debut Nears, Novartis Set to Push Longer Dosing Interval, Pivotal Data in Battle against Eylea
May 22, 2020
BUSINESS
- BMS Taps Ex-Lilly Exec Katsuma as Japan Chief, Sugino as Asia-Pacific GM
January 7, 2025
- Biogen Japan Chief Hopes to Build Momentum in ALS Space Riding on Success with Qalsody
January 7, 2025
- Astellas’ Gastric Cancer Med Vyloy Approved in China
January 7, 2025
- Otsuka/Ionis’ HAE Drug Now under European Review
January 7, 2025
- J&J Bags Kaken’s STAT6 Inhibitor, Set to Take 6% Stake in Japan Firm
December 27, 2024
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…